JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pacher, P.
Right arrow Articles by Szabó, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pacher, P.
Right arrow Articles by Szabó, C.

Vol. 300, Issue 3, 862-867, March 2002

Activation of Poly(ADP-Ribose) Polymerase Contributes to Development of Doxorubicin-Induced Heart Failure

P. Pacher1 , L. Liaudet1 , P. Bai, L. Virag, J. G. Mabley, G. Haskó and C. Szabó

Inotek Corporation, Beverly, Massachusetts (P.P., P.B., L.V., J.G.M.); and Department of Surgery, New Jersey Medical School, University of Medicine and Dentistry New Jersey, Newark, New Jersey (L.L., G.H., C.S.)

Activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) by oxidant-mediated DNA damage is an important pathway of cell dysfunction and tissue injury in conditions associated with oxidative stress. Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin (DOX), a widely used antitumor anthracycline antibiotic. Thus, we hypothesized that the activation of PARP may contribute to the DOX-induced cardiotoxicity. Using a dual approach of PARP-1 suppression, by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34, we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX. PARP-1+/+ and PARP-1-/- mice received a single injection of DOX (25 mg/kg i.p). Five days after DOX administration, left ventricular performance was significantly depressed in PARP-1+/+ mice, but only to a smaller extent in PARP-1-/- ones. Similar experiments were conducted in BALB/c mice treated with PJ34 or vehicle. Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals. In addition PJ34 significantly reduced the DOX-induced increase in the serum lactate dehydrogenase and creatine kinase activities but not metalloproteinase activation in the heart. Thus, PARP activation contributes to the cardiotoxicity of DOX. PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment.

1 P.P. is on leave from the Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungry. L.L. is on leave from the Critical Care Division, Department of Internal Medicine, University Hospital, Lausanne, Switzerland.

0022-3565/02/3003-0862$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
Y. Zhang, H. El-Sikhry, K. R. Chaudhary, S. N. Batchu, A. Shayeganpour, T. O. Jukar, J. A. Bradbury, J. P. Graves, L. M. DeGraff, P. Myers, et al.
Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity
Am J Physiol Heart Circ Physiol, July 1, 2009; 297(1): H37 - H46.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
P. Mukhopadhyay, M. Rajesh, S. Batkai, Y. Kashiwaya, G. Hasko, L. Liaudet, C. Szabo, and P. Pacher
Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro
Am J Physiol Heart Circ Physiol, May 1, 2009; 296(5): H1466 - H1483.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Li, Q. Pan, W. Han, Z. Liu, L. Li, and X. Hu
Schisandrin B Prevents Doxorubicin-Induced Cardiotoxicity via Enhancing Glutathione Redox Cycling
Clin. Cancer Res., November 15, 2007; 13(22): 6753 - 6760.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P. Mukhopadhyay, S. Batkai, M. Rajesh, N. Czifra, J. Harvey-White, G. Hasko, Z. Zsengeller, N. P. Gerard, L. Liaudet, G. Kunos, et al.
Pharmacological Inhibition of CB1 Cannabinoid Receptor Protects Against Doxorubicin-Induced Cardiotoxicity
J. Am. Coll. Cardiol., August 7, 2007; 50(6): 528 - 536.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
P. Pacher, J. S. Beckman, and L. Liaudet
Nitric Oxide and Peroxynitrite in Health and Disease
Physiol Rev, January 1, 2007; 87(1): 315 - 424.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
M. Feletou and P. M. Vanhoutte
Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture)
Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H985 - H1002.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T. L'Ecuyer, S. Sanjeev, R. Thomas, R. Novak, L. Das, W. Campbell, and R. V. Heide
DNA damage is an early event in doxorubicin-induced cardiac myocyte death
Am J Physiol Heart Circ Physiol, September 1, 2006; 291(3): H1273 - H1280.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
P. Pacher, A. Vaslin, R. Benko, J. G. Mabley, L. Liaudet, G. Hasko, A. Marton, S. Batkai, M. Kollai, and C. Szabo
A New, Potent Poly(ADP-ribose) Polymerase Inhibitor Improves Cardiac and Vascular Dysfunction Associated with Advanced Aging
J. Pharmacol. Exp. Ther., November 1, 2004; 311(2): 485 - 491.
[Abstract] [Full Text] [PDF]

Home page
 J. Physiol.Home page
P. Pacher, S. Batkai, and G. Kunos
Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice
J. Physiol., July 15, 2004; 558(2): 647 - 657.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
S. FOGLI, P. NIERI, and M. C. BRESCHI
The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage
FASEB J, April 1, 2004; 18(6): 664 - 675.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
X. Liu, C. C. Chua, J. Gao, Z. Chen, C. L. C. Landy, R. Hamdy, and B. H. L. Chua
Pifithrin-{alpha} protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice
Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H933 - H939.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
P. Pacher, L. Liaudet, P. Bai, J. G. Mabley, P. M. Kaminski, L. Virag, A. Deb, E. Szabo, Z. Ungvari, M. S. Wolin, et al.
Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst Protects Against the Development of Doxorubicin-Induced Cardiac Dysfunction
Circulation, February 18, 2003; 107(6): 896 - 904.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
P.a. Pacher, L. Liaudet, J. G. Mabley, K. Komjati, and C. Szabo
Pharmacologic inhibition of poly(adenosine diphosphate-ribose) polymerase may represent a novel therapeutic approach in chronic heart failure
J. Am. Coll. Cardiol., September 4, 2002; 40(5): 1006 - 1016.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
L. Virag and C. Szabo
The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors
Pharmacol. Rev., September 1, 2002; 54(3): 375 - 429.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.